Related Experiment Videos
Activity of teicoplanin in localized experimental infections in rats
Abstract:
We tested the ability of teicoplanin alone and in combination with rifampicin or gentamicin to cure experimental endocarditis and granuloma pouch infections in rats caused by Streptococcus faecalis, Str. sanguis, methicillin-sensitive and -resistant Staphylococcus aureus. Vancomycin and ampicillin were also tested. Teicoplanin was more active than vancomycin and ampicillin. Combinations of teicoplanin with rifampicin or gentamicin were significantly more effective than single drug therapy. These results suggest that teicoplanin could be an interesting alternative to vancomycin in the treatment of serious streptococcal and staphylococcal infections in man.
Insights
Teicoplanin demonstrated effectiveness against serious streptococcal and staphylococcal infections in rats. Combinations of teicoplanin with rifampicin or gentamicin proved superior to single-drug treatments.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Experimental models are crucial for evaluating novel antimicrobial therapies.
- Streptococcal and staphylococcal infections pose significant clinical challenges.
- Vancomycin is a standard treatment, but resistance and side effects necessitate alternatives.
Purpose of the Study:
- To assess the efficacy of teicoplanin, alone and in combination, against experimental bacterial infections.
- To compare teicoplanin's activity with vancomycin and ampicillin.
- To investigate combination therapies involving teicoplanin with rifampicin or gentamicin.
Main Methods:
- Infection models in rats were established for endocarditis and granuloma pouch infections.
- Bacterial pathogens included Streptococcus faecalis, Streptococcus sanguis, and Staphylococcus aureus (methicillin-sensitive and -resistant strains).
- Treatment groups received teicoplanin, vancomycin, ampicillin, or combinations thereof.
Main Results:
- Teicoplanin exhibited greater antimicrobial activity than vancomycin and ampicillin in vivo.
- Combination therapy with teicoplanin and either rifampicin or gentamicin significantly enhanced treatment outcomes.
- These synergistic effects were observed across various streptococcal and staphylococcal infections.
Conclusions:
- Teicoplanin shows promise as a potent therapeutic agent for severe Gram-positive bacterial infections.
- Combination therapy with teicoplanin offers a potentially more effective treatment strategy.
- Teicoplanin represents a viable alternative to vancomycin for managing challenging streptococcal and staphylococcal infections in humans.